Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
NCT00485719
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
83
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
XL765 (SAR245409)
Sponsor
Sanofi